Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Deferred Revenue (2018 - 2023)

Historic Current Deferred Revenue for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Q2 2023 value amounting to $597000.0.

  • Rocket Pharmaceuticals' Current Deferred Revenue changed 0.0% to $597000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $597000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $597000.0 for FY2022, which is 0.0% changed from last year.
  • As of Q2 2023, Rocket Pharmaceuticals' Current Deferred Revenue stood at $597000.0, which was down 0.0% from $597000.0 recorded in Q1 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Current Deferred Revenue peaked at $597000.0 during Q1 2021, and registered a low of $541000.0 during Q1 2019.
  • Over the past 5 years, Rocket Pharmaceuticals' median Current Deferred Revenue value was $597000.0 (recorded in 2021), while the average stood at $583000.0.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Current Deferred Revenue skyrocketed by 545.81% in 2019, and later changed by 0.0% in 2022.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Current Deferred Revenue stood at $562000.0 in 2019, then rose by 4.98% to $590000.0 in 2020, then grew by 1.19% to $597000.0 in 2021, then changed by 0.0% to $597000.0 in 2022, then changed by 0.0% to $597000.0 in 2023.
  • Its last three reported values are $597000.0 in Q2 2023, $597000.0 for Q1 2023, and $597000.0 during Q4 2022.